July 18, 2026

The Manager - Listing
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400051

The Manager – Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai - 400001

Dear Sir/ Madam

Sub: Business Responsibility and Sustainability Report for the financial year ended March 31, 2026
Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Business Responsibility and Sustainability Report for financial year 2025-26 along with the Independent Practioners' Limited Assurance Report provided by KPMG Assurance and Consulting Services LLP, which also forms part of the Annual Report for financial year 2025-26.

This is for your kind information and records.

Thanking you,

For **AstraZeneca Pharma India Limited**

TANYA SANISH
Digitally signed by TANYA SANISH
Date: 2026.07.18 20:00:14 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer
ACS No. 25784

Encl: as above

Business Responsibility & Sustainability Report

Director's Message

Our commitment to operating a responsible, resilient and sustainable business is reflected in how we manage sustainability-related impacts, risks, and opportunities.

At AstraZeneca, we're committed to improving the health of people, society and the planet. Recognising the strong connection between business growth and resilience, and the need to address the major health challenges of our time, our approach to Sustainability focuses on how we make a sustainable impact and how we do business.

How we make a sustainable impact:
Through the power of science and innovation, we are taking action on climate and nature, health equity and health systems resilience. We collaborate with governments, health systems, patient groups, academia and NGO's to focus our shared efforts where we can have the greatest impact — on local, regional and global health.

How we do business:
We are guided by our Values and invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance.

The interconnection between planetary and population health has never been more evident. Climate change, nature loss, chronic disease burden, ageing populations and strained health systems are converging to threaten progress and widen health inequities, with the greatest impacts felt by the most vulnerable.

As a science-led, patient-focused company, we recognise that addressing these interconnected challenges requires focused action where we can drive meaningful change.

About This Report

We are a global, science-led, patient-focused pharmaceutical business. We are committed to excellence in the research, development and commercialisation of prescription medicines. We aim to transform the lives of patients with improved outcomes and a better quality of life.

Our approach to sustainability
Recognising the interconnection between business growth and addressing the major health challenges of our time, our Sustainability strategy focuses on how we do business and how we make a positive impact — for the health of people, society and the planet.

Section A – General Disclosures

I. Details of the listed entity

1.	**Corporate Identity Number (CIN) of the Listed Entity**	L24231KA1979PLC003563
2.	**Name of the listed entity**	AstraZeneca Pharma India Limited
3.	**Year of incorporation**	1979
4.	**Registered office address**	Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore- 560045, Karnataka, India
5.	**Corporate address**	Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore- 560045, Karnataka, India
6.	**E-mail**	comp.secy@astrazeneca.com
7.	**Telephone**	+91 80 6774 8000
8.	**Website**	www.astrazeneca.com/india
9.	**Financial year for which reporting is being done**	2025-26
10.	**Name of the Stock Exchange(s) where shares are listed**	BSE Limited and National Stock Exchange of India Limited
11.	**Paid-up capital**	INR 50,000,000
12.	**Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report**	Ms. Tanya Sanish Contact no: 080 - 67748000 E-mail Id: comp.secy@astrazeneca.com
13.	**Reporting boundary**	Disclosure under this BRSR is on standalone basis.
14.	**Name of assurance provider**	KPMG Assurance and Consulting Services LLP
15.	**Type of assurance obtained**	Limited Assurance on BRSR Core Indicators only

II. PRODUCTS AND SERVICES

16. Details of business activities (accounting for 90% of the turnover on a standalone basis)

Description of Main Activity	Description of Business Activity	Percentage of Turnover of the entity
Pharmaceuticals	Marketing and trading of pharmaceutical products	90

17. Products/Services sold by the entity (accounting for 90% of the entity's turnover on a consolidated basis)

Product/Service	NIC Code	Percentage of total Turnover contributed
Drugs and Pharmaceutical products	477	100

III. OPERATIONS

18. Number of locations where plants and/or operations/offices of the entity are situatede

Location	Number of plant (including manufacturing plant & warehouse)	Number of offices	Total
National	1*	4	5
International	0	0	0

*During the year under review, manufacturing activities at this site were ceased.

19. Markets served by the entity:

a. Number of locations

Locations	Number
National (Number of States)	Pan-India
International (No. of Countries)	1 (Nepal)

b. What is the contribution of exports as a percentage of the total turnover of the entity?

Out of total turnover of ₹ 22,755.8 million, the export sales contributed ₹ 1,175.6 million (5.2%) during the financial year 2025-26.

c. A brief on types of customers

Our Company's customer base includes distributors, hospitals, and Government institutions.

IV EMPLOYEES

20. Details as at the end of Financial Year

a. Employees and workers (including differently abled):

Sr. No.	Particulars	Total	Male		Female	
			No. of Male Employees	Percentage (%) of the total	No. of Female Employees	Percentage of total
Employees						
1	Permanent	760	558	73	202	27
2	Other than Permanent	0	0	0	0	0
Total employees		**760**	**558**	**73**	**202**	**27**
Workers						
1	Permanent	0	0	0	0	0
2	Other than Permanent	0	0	0	0	0
Total		**0**	**0**	**0**	**0**	**0**

b. Differently abled Employees and workers:

Sr. No.	Particulars	Total	Male		Female	
			No. of Male Employees	Percentage (%) of the total	No. of Female Employees	Percentage of total
Differently Abled Employees						
1	Permanent	1	1	100	0	0
2	Other than Permanent	0	0	0	0	0
Total differently abled employees		**1**	**1**	**100**	**0**	**0**
Workers						
1	Permanent	0	0	0	0	0
2	Other than Permanent	0	0	0	0	0
Total differently abled workers		**0**	**0**	**0**	**0**	**0**

21. Participation/Inclusion/Representation of women

Particulars	Total	No. and percentage of Females	
		No. of women representation	Percentage (%) of total
Board of Directors	6	5	83.33
Key Management Personnel	3	2	66.7

22. Turnover rate for permanent employees and workers (trend for past 3 years)

Particulars	Turnover rate in FY 2025-26 (%)			Turnover rate in FY 2024-25 (%)			Turnover rate in FY 2023-24 (%)		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	17.35	14.85	16.72	25.26	20.74	24.19	11	14	12
Permanent Workers	*NA	*NA	*NA	13.79	37.50	16.67	2	45	6

*NA –Turnover in Permanent Workers is due to redundancies on account of Factory closure in FY 2025-26 i.e. all permanent workers left during the year on account of factory closure.

V. HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES)

23. Names of holding / subsidiary / associate companies / joint ventures

Sr. No.	Name of the holding / subsidiary / associate companies / joint ventures (column A)	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	Percentage (%) of shares held by listed entity	Does the entity indicated in column A participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1	AstraZeneca Pharmaceuticals AB	Holding Company	0	No

VI. CSR DETAILS

24. Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes

I. Turnover – ₹ 22,755.8 million

II. Net worth – ₹ 8,727.9 million

VII. TRANSPARENCY AND DISCLOSURES COMPLIANCES

25. Complaints/Grievances on any of the principles (Principle 1 to 9) under the National Guidelines on Responsible Business Conduct

Stakeholder Group from whom compliant is Received	Grievance Redressal Mechanism in Place (Yes/ No)(If yes, then provide web-link for grievance redress policy)	FY 2025-26			FY 2024-25		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Yes https://www.astrazeneca.in/content/dam/az-in/II-2024/Code%20of%20Ethics.pdf	0	0	NA	0	0	NA

Stakeholder Group from whom compliant is Received	Grievance Redressal Mechanism in Place (Yes/No)(If yes, then provide web-link for grievance redress policy)	FY 2025-26			FY 2024-25		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Shareholders	Yes https://www.astrazeneca.in/investor-relations.html#redressal-of-grievances	1	1	This corresponds to the quarterly disclosures filed with the Stock Exchanges under Regulation 13 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015	1	0	NA
Investors (other than Shareholders)	NA	NA	NA	NA	NA	NA	NA
Employees and workers	Yes Code-of-Ethics-for-the-Employees.pdf	13	0	NA	7	1	NA
Customers	Yes Code-of-Ethics-for-the-Employees.pdf	37	3	Mainly pertain to Product Quality Complaints	45	4	Mainly pertain to Product Quality Complaints
Others (including value chain partners)	Code-of-Ethics-for-the-Employees.pdf	4	0	NA	14	6	NA

26. Overview of the entity's material responsible business conduct issues

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications, as per the following format:

Our materiality assessment is guided by the materiality assessment undertaken by the AstraZeneca Group. The materiality assessment identified the issues that matter most to AstraZeneca's Group companies and stakeholders and showed where AstraZeneca can have a positive impact.

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1.	Climate Action	Opportunity	**We aim to reduce our impact on the planet** As a science-led, patient-focused company, we strive to address the critical link between climate and health. That is why decarbonising our operations and value chain, while advancing sustainable patient care, sits at the heart of our strategy. Through our $1bn Ambition Zero Carbon programme, globally we continue investing in reducing GHG emissions across the research, development, manufacture and supply of our medicines. We have achieved an 88% reduction in Scope 1 and 2 emissions (from our sites and fleet) since 2015 while more than doubling our revenue – demonstrating that we can advance ambitious growth alongside decarbonising our global operations. We continue to make progress toward reducing our Scope 1 and 2 emissions. We are also tackling Scope 3 emissions (value chain), which represent approximately 98% of our total footprint and come primarily from purchased goods and services, capital goods, distribution and product use.	Not Applicable	**Positive** The health of people and the planet are deeply interconnected. At AstraZeneca, we're pioneering sustainable science, manufacturing, and care delivery to improve patient outcomes while reducing the environmental footprint of healthcare. Progress will come from multiple sources: product innovation, including the transition to the next-generation propellant; ongoing supplier engagement; sustainable transport, including shifting from air to sea freight and responsible business travel. Guideline-based care that enables early, targeted and patient-centred interventions, also has an important role to play. By working across and beyond our sector, we can accelerate the decarbonisation of healthcare and contribute to a healthier future.

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
2.	Nature Action	Opportunity	**We aim to actively manage our dependencies and impact on nature** There is a deep connection between population and planetary health, both of which are increasingly affected by nature and biodiversity loss. Natural resources are fundamental not only to our wellbeing but also to the discovery, development, and manufacture of medicines. Grounded in science, our approach to nature follows internationally recognised best practices for measuring, managing and disclosing our environmental impact. By understanding how our business depends on and affects nature, we are taking action on: (a) Sustainable sourcing and resource use: We promote efficient, circular resource use, including water, across our value chain and integrate sustainable sourcing to prevent land use change, deforestation and the exploitation of natural resources. (b) Pollution minimisation: We track our waste circularity rate to maximise material value and eliminate waste in the development, manufacture and delivery of medicines. We are recognised as leaders in our industry in managing pharmaceuticals in the environment (PIE). (c) Nature restoration: We work with stakeholders, including indigenous peoples and local communities, to protect and restore ecosystems, including through global programmes like AZ Forest. We have set 2030 targets that focus on water stewardship and circularity across our sites, complemented by robust governance and metrics to track performance and scale investments to enhance resilience across our value chain.	Not Applicable	**Positive** Protecting nature is fundamental to better health — We depend on it for essential resources, and our communities, economies and society rely on the resilience of its ecosystems. By investing in biodiversity and reducing environmental impacts across our value chain, we're supporting planetary health, for people's health.

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
3.	Improving Health Equity	Opportunity	**We aim to close healthcare gaps to give people everywhere the chance to be as healthy as possible** Our vision is to improve health equity across all healthcare systems and income levels, to remove barriers to healthcare and give everyone the chance to be as healthy as possible. Our work spans across three areas: a) Science: We focus on ensuring our genomics data and research, as well as clinical trials, include people from all backgrounds so that our medicines are effective for a broad range of people and represent those most affected by disease. b) Delivery: We partner with governments and healthcare providers to support more equitable delivery of healthcare - from improving awareness and education, screening and earlier detection to access to medicines. c) Community: We are addressing the root causes of health inequities by helping to prevent disease, promote health and science education, and support health needs in underserved communities through partnerships with non-profit organisations worldwide.	Not Applicable	**Positive** From discovery to delivery: our commitment to health equity. Everyone deserves the opportunity to access quality and timely healthcare, yet it remains out of reach for too many people worldwide. Health outcomes are shaped by multiple, intersecting factors including social, environmental and genetic determinants, that amplify inequities. Those at highest risk of disease often lack timely diagnosis and care, whether in high, middle or low-income countries. We aim to close healthcare gaps across our therapy areas so underserved patients - whether in high, medium, or low- income countries - can benefit from our innovative medicines.
4.	Strengthening health systems resilience	Opportunity	**We aim to contribute to stronger health systems that can meet health needs, today and tomorrow** Ageing populations, a surge in chronic and NCDs, under-investment in healthcare and the climate crisis are all straining health systems globally. As a result, healthcare is becoming more fragmented, reactive and overly dependent on emergency and hospital services. Even advanced health systems struggle to deliver consistently, leaving millions without timely, effective and integrated care. Health systems overwhelmed by today's needs are unprepared for tomorrow's demands. The time to strengthen them is now. Building resilient health systems requires a fundamental shift from treating advanced illness to prevention and early action.		**Positive** Together with partners, we are tackling NCDs through early detection and prevention strategies that deliver better patient outcomes while controlling costs and strengthening sustainability. This depends on addressing the root causes of chronic diseases, enabling earlier access to guideline directed medical therapy and integrating digital innovation. We are co-creating solutions that slow disease progression, reduce hospital admissions and prevent premature deaths, all while helping healthcare professionals deliver more sustainable care. AI and advanced technologies enable us to identify at-risk patients earlier, personalise treatment and respond more efficiently to patient needs.

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
5	How do we do business	Opportunity	**Our Values determine how we work together and the behaviours that drive our success. They guide our decision making and define our beliefs** We follow the Science; We put patients first; We play to Win; We do the right thing; We are entrepreneurial *Our People:* Everything we do is underpinned by being a great place to work. We foster personal growth and enterprise leadership, committed to advancing a culture of lifelong learning across our company so that every employee can continuously develop their skills, capabilities and behaviours, and adapt to future needs. We cultivate an inclusive environment where individuals can authentically express themselves. Our Global Standard for Inclusion and Diversity sets out how we foster an inclusive and diverse workforce where everyone feels valued and respected because of their individual abilities and perspectives. We enable an agile organisation through intuitive tools, technology and optimised ways of working. We are harnessing the potential of technology, simplifying how we work and scaling our business for the future. To do this, we invest in our talent through upskilling and enabling employees to leverage technology and AI in their roles. *Our governance and ethics:* We seek to build long-term resilience and trust We consistently uphold integrity, transparency and fair treatment across our organisation and value chain, enabling us to innovate and operate effectively in support of our purpose. We ensure robust governance. Our Code of Ethics and its supporting Standards are the foundation of our global compliance programme, embodying our Values and expected behaviours. We maintain high standards and accountability. We enforce high standards of conduct and accountability across our business and value chain, supporting partners and building capabilities.		**Positive** Guided by our Values, we invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance. Being purposeful about people, we aim to deliver great employee experiences by being champions of inclusion and diversity while fostering personal growth and enterprise leadership. By embedding ethical behaviour and transparent policies throughout our company activities and value chain, we strive to deliver positive impact that builds on the direct benefits of our life-changing medicines.

Section B: Management and Process Disclosures

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Disclosures Questions	P 1 Ethics and Transparency	P 2 Product Responsibility	P 3 Human Resources	P 4 Responsiveness to Stakeholders	P 5 Human Rights	P 6 Protect & Restore Environment	P 7 Public Policy Advocacy	P 8 Inclusive Growth	P 9 Customer Engagement
Policy and Management Processes									
1. a. Whether your entity's policy/ policies cover each principle and its core elements of the NGRBCs. (Yes/ No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
b. Has the policy been approved by the Board? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
c. Web Link of the Policies, if available	https://www.astrazeneca.in/policy.html								
2. Whether the entity has translated the policy into procedures. (Yes / No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3. Do the enlisted policies extend to your value chain partners? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4. Name of the national and international codes/certifications/ labels/ standards (e.g., Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustee) standards (e.g., SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle	No	No	No	No	No	No	No	No	No
5. Specific commitments, goals and targets set by the entity with defined timelines, if any	-	-	-	-	-	-	-	-	-
6. Performance of the entity against the specific commitments, goals, and targets along with reasons in case the same are not met	-	-	-	-	-	-	-	-	-

Disclosures Questions	P 1 Ethics and Transparency	P 2 Product Responsibility	P 3 Human Resources	P 4 Responsiveness to Stakeholders	P 5 Human Rights	P 6 Protect & Restore Environment	P 7 Public Policy Advocacy	P 8 Inclusive Growth	P 9 Customer Engagement
Governance, Leadership and Oversight									
7. Statement by Director responsible for the business responsibility report, highlighting ESG related challenges, targets, and achievements	Director's Message at the beginning of this Business Responsibility and Sustainability Report.								
8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies)	Name: Mr. Praveen Rao Akkinepally Designation: Managing Director DIN: 11137771								
9. Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes/ No). If yes, provide details	Yes, Mr. Praveen Rao Akkinepally, Managing Director, oversees the Business Responsibility and Sustainability initiatives of the Company.								

10. Details of Review of NGRBCS by the Company

Subject for Review	Review of Principles undertaken by and Frequency
Performance against above policies and follow up action	As a practice, performance against these policies and relevance of the policy is reviewed periodically by department heads and business heads. During such assessment, efficacy of the policies is reviewed and necessary changes to policies and procedures are implemented.
Compliance with statutory requirements of relevance to the principles, and rectification of any non-compliances	The Company is in compliance with regulations, as applicable. The Company reviews on a periodic basis the compliance to statutory requirement.
11. Has the entity carried out independent assessment/evaluation of the working of its policies by an external agency? (Yes/No)	Yes. As part of Companies Act, 2013, the Internal Auditor conducts audit on various sections of the policies which are relevant to their audit scope.

12. If answer to question (1) above is "No" i.e., not all principles are covered by a policy, reason to be stated.

Not Applicable

Section C: Principle-Wise Performance Disclosure

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorised as "Essential" and "Leadership." While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally, and ethically responsible.

PRINCIPLE 1

Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

1. Percentage coverage by training and awareness programmes on any of the principles during the financial year

Segment	Total number of training and awareness programmes held	Topics / principles covered under the training and its impact	Percentage of persons in respective category covered by the awareness programmes
Board of Directors	14	As a part familiarisation programme, the Directors are apprised on various matters relating to the Company's strategy, business financial & operational performance, organisation structure, risk management framework, legal & compliance, human resources, technology, safety, health & environment, regulatory & quality updates, and future outlook. Trainings are also conducted for the KMP's which includes Prevention of Sexual Harassment, Code of Ethics, Cyber Security, Data Privacy, Ergonomics, etc.	100%
Key Managerial Personnel (KMP)			
Employees other than Board of Director (BoD) and Key Managerial Personnel (KMPs)	140	Multiple training programmes covering wide gamut of all principles & topics such as Code of Ethics, Data Privacy, trainings on guidelines pertaining to Prevention of Sexual Harassment, Safety, Heath & Environment, Cyber Security amongst others were given by the company during the year. Further the Company also provides the opportunity for skill upgradation training for the employees & workers.	100%
Workers			

2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format

MONETARY

	NGRBC (National Guidelines on Responsible Business Conduct) Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In INR)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/ Fine					
Settlement			Nil		
Compounding fee					

NON-MONETARY				
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Brief of the Case	Has an appeal been preferred? (Yes/No)
Imprisonment	Nil			
Punishment				

3. **Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.**

   Not Applicable

4. **Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy.**

   Yes, the Company has an anti-corruption and anti-bribery policy. The key principles of the policy are:

   i. We do not tolerate bribery or other forms of corruption, even if we might lose business

   ii. Bribery involves using something of value to improperly influence someone. Something of value includes more than just money

   iii. Bribery risk exists in our interactions with anyone involved in our business, not just public officials

   iv. We do not give or accept bribes, and we do not allow third parties to do so on our behalf.

   Below is the link to our anti-corruption & anti-bribery policy:
   https://www.astrazeneca.in/content/dam/az-in/II-2024/Policy%20on%20Anti-Bribery%20&%20Anti-Corruption.pdf

5. **Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:**

	FY 2025-26	FY 2024-25
Directors	Nil	Nil
KMPs	Nil	Nil
Employees	Nil	Nil
Workers	Nil	Nil

6. **Details of complaints with regard to conflict of interest:**

Particulars	FY 2025-26		FY 2024-25	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	Nil	Nil	Nil	Nil
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	Nil	Nil	Nil	Nil

7. **Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.**

Not Applicable

8. **Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured):**

Particulars	FY 2025-26	FY 2024-25
Number of days of accounts payable	164 days	138 days

9. **Open-ness of business: Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties:**

Parameter	Metrics	FY 2025-26	FY 2024-25
Concentration of Purchases	a. Purchases from trading houses as % of total purchases	0.03	0.04
	b. Number of trading houses where purchases are made from	4	4
	c. Purchases from top 10 trading houses as % of total purchases from trading houses	100	100
Concentration of Sales	a. Sales to dealers / distributors as % of total sales	95.1	96.8
	b. Number of dealers / distributors to whom sales are made	1182	1189
	c. Sales to top 10 dealers / distributors as % of total sales to dealers / distributors	40.9	43.3
Share of RPTs in	a. Purchases (Purchases with related parties / Total Purchases)	82.8	97.9
	b. Sales (Sales to related parties / Total Sales)	5.1	6.1
	c. Loans & advances (Loans & advances given to related parties / Total loans & advances)	NA	NA
	d. Investments (Investments in related parties / Total Investments made)	NA	NA

PRINCIPLE 2

Businesses should provide goods and services in a manner that is sustainable and safe

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

	FY 2025-26	FY 2024-25	Details of improvements in environmental and social impacts
R&D	Nil	Nil	Not Applicable
Capex	Nil	Nil	Not Applicable

2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)

Yes, the Company has procedures in place to implement responsible procurement practices. We expect all employees and contractors to follow our Global Standard for the Procurement of Goods and Services and all our suppliers and partners must meet our Global Standard on Expectations of Third Parties.

b. If yes, what percentage of inputs were sourced sustainably?

All our strategic and critical suppliers are evaluated against AstraZeneca's One procurement Third Party Risk Management (3PRM) process. The 3PRM process covers 12 risk areas including responsible sourcing (including sustainability and conflict minerals). As a practice, the concerned business owner should evaluate the new vendor/supplier/third-party against the 3PRM process before onboarding.

Describe the processes in place to safely reclaim your products for reusing, recycling, and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.

Product Type	Process adopted
(a) Plastics	Company has implemented re-usable eco-wrap (reusable pallet wrap) to reduce single use shrink wrap. Office plastic needs have been replaced with alternatives (plastic bottles replaced with glass bottles and no plastics used in pantry essentials).
(b) E-Waste	We ensure the maximum utilisation of all IT (Information Technology) equipment to its full productive capacity. To extend the useful life of IT equipment, the components of damaged devices are replaced / serviced.
(c) Hazardous waste	All product waste (near to expiry, breakage, and expiry) is collected back from the depots and disposed to KSPCB (Karnataka State Pollution Control Board) authorised recycler.
(D) Other waste	Nil

3. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.

Yes, EPR is applicable to the organisation as we fall in the category of Brand owner and Importers. The Company has obtained registration under Brand owner and importer from Central Pollution Control Board (CPCB). Yes, plastic waste is collected and sent to an authorised recycler.

PRINCIPLE 3

Businesses should respect and promote the well-being of all employees, including those in their value chains

1. a. Details of measures for the well-being of employees:

Category	Total	Employees covered by									
		Health Insurance		Accident Insurance		Maternity Benefits		Paternity Benefits		Day Care	
		Number	%	Number	%	Number	%	Number	%	Number	%
Permanent Employees											
Male	558	558	100	558	100	NA	NA	558	100	NA	NA
Female	202	202	100	202	100	202	100	NA	NA	202	100
Total	**760**	**760**	**100**	**760**	**100**	**202**	**100**	**558**	**100**	**202**	**100**
Other than permanent employees											
Male	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Female	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Total	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**

NA - Not Applicable as no other than permanent employee is employed by the Company

Pursuant to the Labour Codes becoming enforceable from November 21, 2025, a subset of the workforce may qualify for classification as 'workers', and corresponding financial provisions have been recognised in the financial statements. However, the compliance with the Labour Codes are currently being implemented, as applicable.

b. Details of measures for the well-being of workers:

Category	Total	Percentage of workers covered by									
		Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number	%	Number	%	Number	%	Number	%	Number	%
Permanent workers											
Male	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Female	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Total	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**	**NA**
Other than Permanent workers											
Male	NA		NA		NA		NA		NA		NA
Female	NA		NA		NA		NA		NA		NA
Total	**NA**		**NA**		**NA**		**NA**		**NA**		**NA**

Note- No workers at the end of FY 2025-26, hence it is Not applicable.

c. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format

Particulars	FY 2025-26	FY 2024-25
Cost incurred on well-being measures as a % of total revenue of the Company	0.41	0.48

2. Details of retirement benefits, for Current and Previous financial year.

Benefits	FY 2025-26			FY 2024-25		
	No. of employees covered as a percentage of total employees	No. of workers covered as a Percentage of total workers	Deducted and deposited with the authority (Y/N/N.A.)	No. of employees covered as a percentage of total employees	No. of workers covered as a Percentage of total workers	Deducted and deposited with the authority (Y/N/N.A.)
Provident Fund (PF)	100	Nil	Yes	100	100	Yes
Gratuity	100	Nil	Yes	100	100	Yes
Employee State Insurance (ESI)*	NA	NA	NA	NA	NA	NA
Others	NA	NA	NA	NA	NA	NA

*As all the permanent employees and workers are covered by health and accident insurance, Employee State Insurance is not applicable.

3. Accessibility of workplaces

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard: Yes

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.

Yes, the Company highly values the diversity of skills and abilities that a global workforce brings to our business. We are committed to supporting diversity in our workforce and in our leadership and to develop the talent within our organisation. All decisions about recruitment, hiring, compensation, development and promotion must be made solely on the basis of a person's ability, experience, behaviour, work performance and demonstrated potential in relation to the needs of the job. The same has been further detailed in company's Code of Conduct document which can be accessed in the company's website - Code of Ethics.pdf

5. Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender	Permanent employees		Permanent workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	100%	100%	Nil	Nil
Female	100%	100%	Nil	Nil
Total	**100%**	**100%**	**Nil**	**Nil**

6. **Is there a mechanism available to receive and redress grievances for the following categories of employees and workers? If yes, give details of the mechanism in brief.**

Particulars	Yes/No	(If yes, then give details of the mechanism in brief)
Permanent Workers	Yes	We have established an AZ Ethics portal available to all workers, to report concerns. Workers are also motivated to raise their concerns or grievances during the monthly and quarterly meetings.
Other than Permanent Workers	Not Applicable	Not Applicable
Permanent Employees	Yes	Similar to workers, an AZ Ethics portal is available to all employees, to report concerns or grievances. Further, the company has established a formal Grievance Redressal Policy.
Other than Permanent Employees	Not Applicable	Not Applicable

7. **Membership of employees and worker in association(s) or Unions recognised by the listed entity:**

Category	FY 2025-26			FY 2024-25		
	Total employees / workers in respective category	No. of employees / workers in respective category, who are part of association(s) or Union	%	Total employees / workers in respective category	No. of employees / workers in respective category, who are part of association(s) or Union	%
Total Permanent Employees	**760**	**0**	**0**	**747**	**0**	**0**
Male	558	0	0	572	0	0
Female	202	0	0	175	0	0
Total Permanent Workers	**0**	**0**	**0**	**55**	**55**	**100**
Male	0	0	0	50	50	100
Female	**0**	**0**	**0**	**5**	**5**	**100**

8. **Details of training given to employees and workers:**

Category	FY 2025-26					FY 2024-25				
	Total (A)	On Health and safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		Number	%	Number	%		Number	%	Number	%
Permanent Employees										
Male	558	558	100	558	100	572	572	100	572	100
Female	202	202	100	202	100	175	175	100	175	100
Total	**760**	**760**	**100**	**760**	**100**	**747**	**747**	**100**	**746**	**100**
Permanent Workers										
Male	0	0	0	0	0	50	50	100	50	100
Female	0	0	0	0	0	5	5	100	5	100
Total	**0**	**0**	**0**	**0**	**0**	**55**	**55**	**100**	**55**	**100**

9. Details of performance and career development reviews of employees and worker:

Category	FY 2025-26			FY 2024-25		
	Total	Number	%	Total	Number	%
Employees						
Male	558	558	100	572	572	100
Female	202	202	100	175	175	100
Total	**760**	**760**	**100**	**742**	**742**	**100**
Workers						
Male	0	0	0	50	50	100
Female	0	0	0	5	5	100
Total	**0**	**0**	**0**	**55**	**55**	**100**

10. Health and safety management system:

a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage of such a system?

Yes- SHE (Safety Health & Environment) Management system has been implemented as per Global SHE.

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

There are processes adopted to identify and mitigate work-related hazards and assess the risks, including:

- Process & procedures related to SHE
- Occupational and Industrial hygiene risk assessments.

c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks. (Y/N)

Yes, the company has process for workers to report unsafe acts and conditions through a STOP card system and online reporting tool as per the AZ SHE System. During the year under review, manufacturing activities at the site were ceased.

d. Do the employees/workers of the entity have access to non-occupational medical and healthcare services? (Yes/ No)

Yes, the company has tie-ups with multiple hospitals chains as part of employee insurance. Employees/workers can access those hospital chains and claim the amount as covered under insurance.

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category	FY 2025-26	FY 2024-25
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	2.94	4.78*
	Workers	0	0
Total recordable work-related injuries	Employees	5	8*
	Workers	0	0
No. of fatalities	Employees	0	0
	Workers	0	0
High consequence work-related injury or ill-health (excluding fatalities)	Employees	0	0
	Workers	0	0

*The comparative figures for the financial year 2024–25 have been restated in line with the methodology contained in the Guidance Note on BRSR (Annexure 17 to the SEBI Master Circular dated January 30, 2026) and the Industry Standards on Reporting of BRSR Core (the Industry Standards).

12. Describe the measures taken by the company to ensure a safe and healthy workplace.

The company has adopted several initiatives for ensuring a safe and healthy workplace for its employees and workers.

- SHE policy, part of the company's code of ethics and SHE Management system has been adopted by the company
- Road accidents have been identified as a major hazard for field employees. Below are the mitigation measures adopted:
  - Defensive driving training is imparted to the employees during induction
  - Crash helmet is being provided to 2-wheeler users
  - Safety riding jacket is being provided to 2-wheeler users
- Fire has been identified as a hazard for office-based employees. Below are the mitigation measures:
  - Fire safety equipment has been installed as per requirement
  - Biannual evacuation mock drills are conducted for the corporate office
  - Evacuation mock drills are conducted for factory as per the statutory requirements.

13. Number of Complaints on the following made by employees and workers:

Particulars	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	Nil	Nil	-	Nil	Nil	-
Health & Safety	Nil	Nil	-	Nil	Nil	-

14. Assessments for the year:

Particulars	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	None
Working Conditions	None

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.

Safety related accidents relate to road accidents. In this case each accident is investigated, and root cause analysis (RCA) exercise is carried out. The corrective action is then circulated via mailer to the organisation and separately to the concerned employee.

PRINCIPLE 4

Businesses should respect the interests of and be responsive to all its stakeholders

1. **Describe the processes for identifying key stakeholder groups of the entity.**
   Stakeholder mapping / identification is done based on the analysis of the stakeholder groups that could have potential impact on our business operations as well as the impact which the company might have on them.

2. **List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.**

Stakeholder Group	Whether identified as Vulnerable & Marginalised Group (Yes/ No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Healthcare Professionals (HCP's)	No	Regular business interactions through Conferences, Surveys, Face to Face meetings, Virtual interactions and Company organised meetings.	Regular / As per practice	- Information in and around the product and therapy area - Frequent engagement andunderstanding HCP's andpatient's need - Responding to queries
Regulators	No	- Regulatory filings - E-Mail communications - Community meetings (Industry organisation meetings)	Need Based	- Regulatory Compliances - Responding to regulatory queries - Regulatory Submissions - Corporate Governance
Investors / Shareholders	No	- Annual reports & Annual General Meeting - Quarterly reports filed through stock exchanges - Material Announcements through stock exchange	Annually Quarterly Event - based	- Performance & Financial results - Corporate Governance - Transparency in Disclosures
Employees	No	- Townhall Meetings - Performance Appraisals reviews - Emails & Meetings - Training Programmes - Employee Engagement Programmes such as Regional Business Meets, National Strategy Meet, Offsites	Regular / As per practice	- Training, Professional Growth & Development - Well-being initiatives - Employee Recognitions - Updates & Communications on policies, processes & systems.
Suppliers	No	- Emails & Meetings - Supplier Assessment & Reviews - Regular Business Interactions	Regular / As per practice	- Supplier Assessments - Promoting Shared Growth - Payments & Collaborations
Community	Yes	- Health Day Celebrations - CSR Projects	Regular / As per practice	- Increasing awareness & understanding of non-communicable disease - CSR Activities/ PAG Engagements
Industry Associations	No	- Email - In-person - SVirtual meetings	Need-basis	- Policy Shaping

PRINCIPLE 5

Businesses should respect and promote human rights

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

Category	FY 2025-26			FY 2024-25		
	Total	Number	%	Total	Number	%
Employees						
Permanent	760	760	100	747	747	100
Other than permanent	0	0	0	0	0	0
Total	**760**	**760**	**100**	**747**	**747**	**100**
Workers						
Permanent	0	0	0	55	55	100
Other than permanent	0	0	0	0	0	0
Total	**0**	**0**	**0**	**55**	**55**	**100**

2. Details of minimum wages paid to employees and workers, in the following format:

Category	FY 2025-26					FY 2024-25				
	Total	Equal to Minimum Wage		More than Minimum Wage		Total (D)	Equal to Minimum Wage		More than Minimum Wage	
		Number	%	Number	%		Number	%	Number	%
Permanent Employees										
Male	558	0	0	558	100	572	0	0	572	100
Female	202	0	0	202	100	175	0	0	175	100
Other than Permanent Employees										
Male	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Female	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Permanent Workers										
Male	0	0	0	0	0	50	0	0	50	100
Female	0	0	0	0	0	5	0	0	5	100
Other than Permanent Workers										
Male	0	0	0	0	0	NA	NA	NA	NA	NA
Female	0	0	0	0	0	NA	NA	NA	NA	NA

*Not Applicable as no other than permanent employees and worker are employed by the Company

3. Details of remuneration/salary/wages, in the following format:

a. Median remuneration / wages:

Category	Male		Female	
	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration/ salary/ wages of respective category
Directors	2	2,41,91,209	1	2,56,30,777
Key Managerial Personnel (KMP)	2	2,41,91,209	3	26,56,600
Employees	557	21,63,268	200	20,98,446
Workers	0	0	0	0

Note: There are three Board members who are also part of the KMP and their details are accordingly reported under both categories.

Note:

1. Sanjeev Kumar Panchal was a Managing Director and a KMP upto June 30, 2025
2. Praveen Rao Akkinepally was appointed as a Managing Director and KMP w.e.f. July 1, 2025 onwards
3. Bhavana Agrawal is a Director and a KMP
4. Manasa R was the Company Secretary and Compliance Office upto November 28, 2025
5. Tanya Sanish was appointed as a Company Secretary and Compliance Office w.e.f. February 23, 2026 onwards

b. Gross wages paid to females as % of total wages paid by the entity:

Particulars	FY 2025-26	FY 2024-25
Gross wage paid to females as % of total wages	25.54	19.88

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes, the Head of Human Resource is responsible for addressing human rights impacts. The company supports the principles set out in the UN Declaration of Human Rights, and our policies detail our high standards of employment practice. These include respecting diversity and, as a minimum, complying with national legal requirements regarding wages and working hours. We also support the International Labour Organization's standards ratified by India.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

Website (AZethics.com), email id (GlobalCompliance@astrazeneca.com) form a part of mechanism in place for grievance redressal on human rights issues. The Company's code of conduct includes details on HOW TO ASK A QUESTION OR RAISE A CONCERN. Grievances can also be shared anonymously, and efforts are taken to ensure that the information is kept confidential and communicated on a need-to-know basis.

AZethics.com are managed by a third party on AstraZeneca's behalf. Consent of persons who connect is sought in order to disclose their contact information.

6. Number of Complaints on the following made by employees and workers:

Category	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of the year	Remarks	Filed during the year	Pending Resolution at the end of the year	Remarks
Sexual Harassment	Nil	Nil	NA	1	Nil	None
Discrimination at workplace	Nil	Nil	NA	Nil	Nil	None
Child Labour	Nil	Nil	NA	Nil	Nil	None
Forced Labour/Involuntary	Nil	Nil	NA	Nil	Nil	None
Wages	Nil	Nil	NA	Nil	Nil	None
Other Human rights related	Nil	Nil	NA	Nil	Nil	None

7. Complaints filed under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

Particulars	FY 2025-26	FY 2024-25
Total Complaints reported under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	Nil	1
Complaints on POSH as a % of female employees/workers	Nil	0.56%
Complaints on POSH upheld	Nil	2

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

The company has established a formal “Bullying and Harassment Policy” to prevent adverse consequences to the complainant in discrimination and harassment cases. The policy is made available to all permanent employees and workers for their reference. Further, the policy sets out the guidelines for managers and employees on how to handle situations in which employees are being exposed to bullying or harassing actions.

9. Do human rights requirements form part of your business agreements and contracts? (Yes/No)

Yes, Abiding by Human rights requirements is part of the contract document with all the contractors. Reference company’s policy on “Expectations of Third Parties”

10. Assessments for the year:

Category	% of plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100
Forced/involuntary labour	100
Sexual harassment	100
Discrimination at workplace	100
Wages	100

11. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above.

Not applicable, since no such incidents were reported.

PRINCIPLE 6

Businesses should respect and make efforts to protect and restore the environment

Note: The reporting boundary for FY 2025-26 includes shared office spaces in addition to the locations covered in FY 2024-25, one of which is a manufacturing facility. The manufacturing facility underwent decommissioning during the reporting period.

Essential Indicators

1. Details of total energy consumption (in Giga Joules or multiples) and energy intensity:

Parameter	FY 2025-26	FY 2024-25
From renewable sources		
Total electricity consumption (A)	6877.54 GJ	12,301.2 GJ
Total fuel consumption (B)	0	0
Energy consumption through other sources (C)	0	0
Total energy consumed from renewable sources (A+B+C)	**6877.54 GJ**	**12,301.2 GJ**

Parameter	FY 2025-26	FY 2024-25
From non-renewable sources		
Total electricity consumption (D)	2275.02 GJ	6,109.14 GJ
Total fuel consumption (E)	1324.64 GJ	4,517.2 GJ
Energy consumption through other sources (F)		0
Total energy consumed from non-renewable sources **(D+E+F)**	**3599.60 GJ**	**10,626.34 GJ**
Total energy consumed **(A+B+C+D+E+F)**	**10477.20 GJ**	**22,927.55 GJ**
Energy intensity per rupee of turnover (Total energy consumed / Revenue from operations) (GJ/₹ million)	0.46	1.33
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total energy consumed / Revenue from operations adjusted for PPP) (GJ/₹ million adjusted for PPP)	9.4	27.6
Energy intensity in terms of physical output	13.79	253.39

Note: For shared office spaces with limited operational control, consumption has been determined on an estimation basis.

Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency -
Yes, an independent assessment with respect to the above parameters has been carried out by M/s. KPMG Assurance and Consulting Services LLP.

2. **Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any -**

   No, none of the sites / facilities were identified as designated consumers.

3. **Provide details of the following disclosures related to water:**

Parameter	FY 2025-26	FY 2024-25
Water withdrawal by source (in kiloliters)		
(i) Surface water	0	0
(ii) Groundwater	7620.03	22,047.26
(iii) Third party water	583.29	92.17
(iv) Seawater / desalinated water	0	0
(v) Others		394.84
Total volume of water withdrawal (in kiloliters) (i + ii + iii + iv + v)	**8203.32**	**22,534.27**
Total volume of water consumption (in kiloliters)	**7691.06**	**22,150.22**
Water intensity per rupee of turnover (Water consumed / turnover in Million rupee)	**0.34**	**1.29**
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total water consumption / Revenue from operations adjusted for PPP) (in kiloliters/₹ million adjusted for PPP)	6.875	26.66
Water intensity in terms of physical output (KL/MT)	10.12	244.8

Note: Water consumption for certain locations has been estimated using the CGWA-guideline of per capita consumption norm of 45 litres per person per day.

Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency –
Yes, an independent assessment with respect to the above parameters has been carried out by M/s. KPMG Assurance and Consulting Services LLP

4. Provide the following details related to water discharged

Parameter	FY 2025-26	FY 2024-25
Water discharge by destination and level of treatment (in kilolitres)		
(i) Surface water	Nil	Nil
- No treatment	0	0
- With treatment – please specify level of treatment	0	0
(ii) Groundwater	Nil	Nil
- No treatment	0	0
- With treatment – please specify level of treatment	0	0
(iii) Seawater / desalinated water	Nil	Nil
- No treatment	0	0
- With treatment – please specify level of treatment	0	0
(iv) Sent to third parties	Nil	Nil
- No treatment	0	0
- With treatment – please specify level of treatment	0	0
(v) Others	512.26	316.91
- No treatment	0	0
- With treatment – used for Landscaping	0	67.12
Total water discharged (in kiloliters)	**512.26**	**384.04**

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

Yes, generated effluent is 100% treated in-house Combined Effluent Treatment Plant and used within the manufacturing plant for landscaping.

6. Please provide details of air emissions (other than GHG emissions) by the entity:

Parameter	Please specify unit	FY 2025-26	FY 2024-25
NOx (Nitrogen oxides)	mg/Nm3	0	15.0
SOx (Sulphur oxides)	mg/Nm3	0	8
Particulate matter (PM)	mg/Nm3	0	43.5
Persistent organic pollutants (POP)	mg/Nm3	0	Not Applicable
Volatile organic compounds (VOC)	mg/Nm3	0	Not Applicable
Hazardous air pollutants (HAP)	mg/Nm3	0	Not Applicable
Others – Carbon Monoxide	mg/Nm3	0	Nil

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency -

No independent assessment has been carried out.

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity:

Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tonnes of CO2 equivalent	88.31	312.04
Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tonnes of CO2 equivalent	452.70	1,233.65
Total Scope 1 and Scope 2 emissions intensity per rupee of turnover (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)	Metric tonnes of CO2 eq./₹ turnover in Million rupee	0.024	0.09
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations adjusted for PPP)	Metric tonnes of CO2 eq./₹ turnover in Million rupee adjusted for PPP	0.48	1.86
Total Scope 1 and Scope 2 emission intensity in terms of physical output	tCO2e / Metric Tonnes of Production	0.71	17.08

8. Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details.

No, on account of cessation of manufacturing activity at the plant during the year.

9. Provide details related to waste management by the entity:

Parameter	FY 2025-26	FY 2024-25
Total Waste generated (in metric tonnes)		
Plastic waste (A)	0.02	0.10
E-waste (B)	0.04	0.58
Bio-medical waste (C)	0.00	0.0069
Construction and demolition waste (D)	Nil	Nil
Battery waste (E)	0.39	0.04
Radioactive waste (F)	Nil	Nil
Other Hazardous waste. Please specify, if any. (G)	2.77	18.91
Other Non-hazardous waste generated (H). Please specify, if any. (Break-up by composition i.e., by materials relevant to the sector)	7.68	6.63
Total (A+B + C + D + E + F + G + H)	**10.89**	**26.26**
Waste intensity per rupee of turnover (Total waste generated/revenue from operations) (in metric tonne/₹ million)	0.0005	0.0015
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total waste generated/revenue from operations adjusted for PPP) (in metric tonne/₹ million adjusted for PPP)	0.01	0.31
Waste intensity in terms of physical output	0.01	0.29

For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)

Parameter	FY 2025-26	FY 2024-25
Category of waste		
(i) Recycled	0.30	6.09
(ii) Re-used	0.88	NA
(iii) Other recovery operations	0.39	NA
Total	**1.57**	**6.09**
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)		
Category of waste		
(i) Incineration	NA	18.84
(ii) Landfilling	NA	NA
(iii) Other disposal operations	17.2	1.442
Total	**17.2**	**20.282**

Note: Waste quantities for locations where the Company has limited operational control have been determined on an estimation basis.

Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency -
Yes, an independent assessment with respect to the above parameters has been carried out by M/s. KPMG Assurance and Consulting Services LLP

10. **Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.**
    - Non-hazardous waste is disposed to Bruhat Bengaluru Mahanagara Palika (BBMP) authorised vendor
    - Hazardous waste is disposed to KSPCB authorised recycler
    - The company envisages to reduce its waste reduction through its waste reduction programmes.

11. **If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:**

    Not applicable.

12. **Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:**

    No Environmental Impact Assessment (EIA) study has been undertaken in the current financial year.

13. **Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:**

    Yes, the organisation is abiding by all the applicable laws. The organisation is complying with conditions obtained from KSPCB, Hazardous waste authorisation, Biomedical waste authorisation consents.

PRINCIPLE 7

Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

1.

a. Number of affiliations with trade and industry chambers/ associations.

The Company has affiliation with one (1) trade and industry chambers/association.

b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to.

S. No.	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations (State/National)
1.	Organisation of Pharmaceutical Producers of India	National

2. Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by the entity, based on adverse orders from regulatory authorities

There are no adverse orders passed against the Company in relation to anti-competitive conduct.

PRINCIPLE 8

Businesses should promote inclusive growth and equitable development

1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.

In the reporting year, the Company did not undertake any Social Impact Assessment.

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:

In the reporting year, the Company did not undertake any Rehabilitation and Resettlement (R&R) for any project(s).

3. Describe the mechanisms to receive and redress grievances of the community.

Website (AZethics.com), email id (GlobalCompliance@astrazeneca.com) form a part of mechanism in place for grievance redressal on human rights issues. The Company's code of conduct include details on HOW TO ASK A QUESTION OR RAISE A CONCERN. Grievances can also be shared anonymously and efforts are taken to ensure that the information is kept confidential and communicated on a need-to-know basis.

AZethics.com are managed by a third party on AstraZeneca's behalf. When someone ask a question or raise concern, their wish to disclose contact information is checked.

4. **Percentage of input material (inputs to total inputs by value) sourced from suppliers:**

	FY 2025-26	FY 2024-25
Directly sourced from MSMEs/ small producers	3%	0.5%
Sourced directly from within the district and neighboring districts	16.9%	2.2%

5. **Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent/ or contract basis) in following locations, as % of total wage cost:**

Location	FY 2025-26	FY 2024-25
Rural	0	0
Semi – Urban	0.14	1.6
Urban	11.50	3.6
Metropolitan	88.36	94.8

PRINCIPLE 9

Businesses should engage with and provide value to their consumers in a responsible manner

1. **Describe the mechanisms in place to receive and respond to consumer complaints and feedback.**
The Company has a dedicated email id and online tool/questionnaire available on AZ India Website to register any complaint relating to product quality. These complaints are automatically processed in the tool where the relevant quality team are assigned to work upon the complaint resolution. The investigation report is then shared with the complaint owner.

2. **Turnover of products and/ services as a percentage of turnover from all products/service that carry information about**

Category	As a percentage to total turnover
Environmental and social parameters relevant to the product	-
Safe and responsible usage	100%
Recycling and/or safe disposal	-

3. **Number of consumer complaints in respect of the following:**

Category	FY 2025-26			FY 2024-25		
	Received during the year	Pending resolution at the end of the year	Remarks	Received during the year	Pending resolution at the end of the year	Remarks
Data privacy	0	0	Nil	0	0	Nil
Advertising	0	0	Nil	0	0	Nil
Cyber-security	0	0	Nil	0	0	Nil
Delivery of essential services	0	0	Nil	0	0	Nil
Restrictive Trade Practices	0	0	Nil	0	0	Nil
Unfair Trade Practices	0	0	Nil	0	0	Nil
Other	4	0	Nil	1	0	Nil

4. Details of instances of product recalls on account of safety issues:

Category	Number	Reasons for recall
Voluntary recalls	Nil	Not Applicable
Forced recalls	Nil	Not Applicable

5. Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy.

Yes, the Company has a policy on cyber security - https://www.astrazeneca.in/policy.html

6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.

There has been no instance of any corrective actions taken or underway on re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services in recent past.

7. Provide the following information relating to data breaches:

(a) Number of instances of data breaches: 0

(b) Percentage of data breaches involving personally identifiable information of customers: 0

(c) Impact, if any, of the data breaches: None

KPMG

KPMG Assurance and Consulting Services LLP
Building No. 10, Tower C, 4th Floor,
DLF Cyber City, Phase II
Gurugram, Haryana – 122002
India
Telephone: +91 124 3369000

Independent Practitioners' Limited Assurance Report

To the Directors of AstraZeneca Pharma India Limited

Assurance report on sustainability disclosures in the Business Responsibility and Sustainability Reporting (BRSR) Core Format.

Assurance report on the sustainability disclosures in the Business Responsibility and Sustainability Reporting (BRSR) Core Format[1] (called 'Identified Sustainability Information' (ISI) of AstraZeneca Pharma India Limited (the 'Company') for the period 1 April 2025 to 31 March 2026. The ISI is included in the Business Responsibility and Sustainability Reporting of the Company in the Annual Report for the period from 1 April 2025 to 31 March 2026.

Conclusion

We have performed an assurance engagement on the Identified Sustainability Information (ISI) as detailed in the table below:

Identified Sustainability Information (ISI) subject to assurance	**Period subject to assurance**	**Page number in the Annual Report**	**Reporting criteria**
BRSR Core (refer Annexure 1)	1 April 2025 to 31 March 2026	BRSR section of Annual Report	- Regulation 34(2)(f) of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (SEBI LODR) - Master Circular for compliance with the provisions of the SEBI LODR by listed entities, dated January 30, 2026 (Master Circular) prescribing o Format of the BRSR o Guidance notes for BRSR format - Greenhouse Gas (GHG) Protocol (A Corporate Accounting and Reporting Standard) (Revised) developed by World Resources Institute (WRI) / World Business Council for Sustainable Development (WBCSD)

This engagement was conducted by a multidisciplinary team including assurance practitioners, engineers and environmental and social professionals.

[1] *Notified by SEBI vide circular number* ***SEBI/HO/CFD/CFD-SEC-2/P/CIR/2023/122 dated 12 July 2023***

KPMG Assurance and Consulting Services LLP Gurugram

Based on the procedures performed and evidence obtained, nothing has come to our attention to cause us to believe that the company's Identified Sustainability Information of the Annual Report relating to BRSR core attributes for the year ended 31 March 2026, is not prepared, in all material respects, in accordance with Regulation 34(2)(f) of the SEBI LODR, *Master Circular, Greenhouse Gas (GHG) Protocol (A Corporate Accounting and Reporting Standard) (Revised))* and basis of preparation set out in set out in Section A: Question 13 of the BRSR.

Basis for conclusion

We conducted our engagement in accordance with International Standard on Assurance Engagements (ISAE) 3000 (Revised), *Assurance Engagements Other Than Audits or Reviews of Historical Financial Information* and ISAE 3410, *Assurance Engagements on Greenhouse Gas Statements*, issued by the International Auditing and Assurance Standards Board (IAASB). Our responsibilities under those standards are further described in the "Our responsibilities" section of our report.

We have complied with the independence and other ethical requirements of the International Code of Ethics for Professional Accountants (including International Independence Standards) issued by the International Ethics Standards Board for Accountants (IESBA).

Our firm applies International Standard on Quality Management (ISQM) 1, *Quality Management for Firms that Perform Audits or Reviews of Financial Statements, or Other Assurance or Related Services Engagements*, issued by the IAASB. This standard requires the firm to design, implement and operate a system of quality management, including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.

Other information

Management and the Board of Directors are responsible for the other information. The other information comprises the information included in the Company's Annual Report (but does not include the BRSR Core attributes and assurance report thereon). The Company's Annual Report is expected to be made available to us after the date of this assurance report.

Our limited assurance conclusion on BRSR core attributes does not cover the other information and we are not expressing any form of assurance conclusion thereon.

In connection with our assurance on the BRSR Core attributes, our responsibility is to read the other information identified above when it becomes available, and in doing so, consider whether other information is materially inconsistent with the BRSR Core attributes, or our knowledge obtained in the assurance, or otherwise appears to be materially misstated.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to Those Charged With Governance and describe actions applicable under the applicable laws and regulations.

Other matter

The BRSR for the period 1 April 2024 to 31 March 2025 was not subject to limited/reasonable assurance and accordingly, we do not express an opinion/conclusion or provide any assurance on such information.

Our conclusion is not modified with respect to this matter.

Intended use or purpose

The ISI and our limited assurance report are intended for users who have reasonable knowledge of the BRSR Core attributes, the reporting criteria and ISI and who have read the information in the ISI with reasonable diligence and understand that the ISI is prepared and assured at appropriate levels of

KPMG Assurance and Consulting Services LLP Gurugram

materiality.

Our conclusion is not modified in respect of this matter.

Management's responsibilities for Identified Sustainability Information (ISI)

The management of the company are responsible for:

- designing, implementing and maintaining internal control relevant to the preparation of the Identified Sustainability Information that is free from material misstatement, whether due to fraud or error;
- selecting or establishing suitable criteria for preparing the ISI, taking into account applicable laws and regulations, if any, related to reporting on the ISI, identification of key aspects, engagement with stakeholders, content, preparation and presentation of the ISI in accordance with the Reporting Criteria;
- disclosure of the applicable criteria used for preparation of the ISI in the (Integrated, if applicable) Annual Report;
- preparing/fairly stating/properly calculating the ISI in accordance with the reporting criteria.
- ensuring the reporting criteria is available for the intended users with relevant explanation;
- establishing targets, goals and other performance measures, and implementing actions to achieve such targets, goals and performance measures;
- providing the details of the management personnel who takes ownership of the ISI disclosed in the report;
- ensuring compliance with laws, regulations or applicable contracts;
- making judgements and estimates that are reasonable in the circumstances;
- identifying and describing any inherent limitations in the measurement or evaluation of information covered by assurance in accordance with the reporting criteria;
- preventing and detecting fraud;
- selecting the content of the ISI, including identifying and engaging with intended users to understand their information needs;
- informing us of other information that will be included with the ISI;
- supervision of other staff involved in the preparation of the ISI.

Those charged with governance are responsible for overseeing the reporting process for the company's ISI.

Inherent limitations

The preparation of the company's sustainability information requires the management to establish or interpret the criteria, make determinations about the relevancy of information to be included, and make estimates and assumptions that affect the reported information.

Measurement of certain amounts and BRSR Core attributes, some of which are estimates, is subject to substantial inherent measurement uncertainty, for example GHG emissions, water footprint, energy footprint. Obtaining sufficient appropriate evidence to support our opinion/conclusion does not reduce the uncertainty in the amounts and metrics.

KPMG Assurance and Consulting Services LLP Gurugram

Our responsibilities

We are responsible for:

- planning and performing the engagement to obtain a limited assurance about whether the ISI is free from material misstatement, whether due to fraud or error;
- forming an independent conclusion, based on the procedures we have performed and the evidence we have obtained; and
- reporting our conclusion to the Board of Directors of the Company.

Summary of the work we performed as the basis for our conclusion

We exercised professional judgement and maintained professional skepticism throughout the engagement. We designed and performed our procedures to obtain evidence that is sufficient and appropriate to provide a basis for limited assurance conclusion.

Our selected procedures depended on our understanding of the information covered by limited assurance and other engagement circumstances, and our consideration of areas where material misstatements are likely to arise. In carrying out our engagement, we:

- assessed the suitability of the criteria used by the company in preparing the information covered by limited assurance;
- interviewed senior management and relevant staff at corporate and selected locations concerning policies for occupational health and safety, and the implementation of these across the business;
- through inquiries, obtained an understanding of AstraZeneca Pharma India Limited's control environment, processes and information systems relevant to the preparation of the information covered by limited assurance, but did not evaluate the design of particular control activities, obtain evidence about their implementation or test their operating effectiveness;
- made inquiries of relevant staff at corporate and selected locations responsible for the preparation of the information covered by limited assurance;
- undertook 3 site visits covering the Head Office, the Manufacturing Plant in Bengaluru, and the Leased Office Space in Gurugram. The office locations were selected based on their significance to the environmental disclosures, considering the relative size of their workforce and office area in relation to the Company's total workforce and overall office footprint. The Manufacturing Plant was selected based on its materiality to the reported disclosures and its ongoing decommissioning during the reporting period.
- inspected, at each site visited, a limited number of items to or from supporting records, as appropriate;
- applied analytical procedures, as appropriate;
- recalculated the information covered by limited assurance based on the criteria; and
- evaluated the overall presentation of the information covered by limited assurance to determine whether it is consistent with the criteria and in line with our overall knowledge of, and experience with, the company's policies relating to occupational health and safety.

The procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.

Exclusions

Page **4** of **7**

KPMG Assurance and Consulting Services LLP Gurugram

Our assurance scope excludes the following and therefore, we will not express a conclusion on the same:

- Any form of review of the commercial merits, technical feasibility, accuracy of claims, compliance with applicable legislations. We have not verified any of the judgements in relation to commercial risks associated with the business activities.
- Operations of the Company other than those under the *Reporting Boundary set out in the section A of BRSR section of the Annual Report* (Scope of Assurance).
- The Company's statements that describe the strategy, progress on goals (other than those listed under the scope of assurance, as mentioned above), expression of opinion, claims, belief, aspiration, expectation, aim to future intention provided by the Company, and assertions related to Intellectual Property Rights and other competitive issues.
- Aspects of the BRSR Core attributes and the data/information (qualitative or quantitative) other than the ISI.
- Data and information outside the defined reporting period i.e., 1 April 2025 to 31 March 2026.

KPMG Assurance and Consulting Services LLP Gurugram

Ravi Kant Thakur
Partner
KPMG Assurance and Consulting Services LLP
Date:17 July 2026
Place: Gurugram

KPMG

Appendix – 1

BRSR Core Attributes-Limited Assurance for FY 2025-2026

Principle	Attribute / Area	Parameter / Metric
Principle 1 - E8	Fairness in Engaging with Customers and Suppliers	Number of days of accounts payable
Principle 1 - E9	Open-ness of business	Concentration of purchases & sales done with trading houses, dealers, and related parties Loans and advances & investments with related parties
Principle 3 - E1 c	Enhancing Employee Wellbeing and Safety	Spending on measures towards well-being of employees and workers
Principle 3 - E11		Details of safety related incidents (LTIFR, Recordable Injuries, Fatalities, High Consequence Injuries)
Principle 5 - E3 b	Enabling Gender Diversity in Business	Gross wages paid to females as percentage of total wages paid by the entity
Principle 5 - E7		Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013
Principle 6 - E1	Energy Footprint	Total energy consumption
		Percentage of energy consumed from renewable sources
		Energy intensity (per rupee of turnover, per rupee of turnover adjusted for PPP, per physical output)
Principle 6 - E3	Water Footprint	Total water consumption
		Water consumption intensity (per rupee of turnover, per rupee of turnover adjusted for PPP, per physical output)
Principle 6 - E4	Water Footprint	Water Discharge by destination and levels of Treatment
Principle 6- E7	GHG Footprint	Total Scope 1 emissions (Break-up of the GHG into CO_2, CH_4, N_2O, HFCs, PFCs, SF_6, NF_3, if available)
		Total Scope 2 emissions (Break-up of the GHG into CO_2, CH_4, N_2O, HFCs, PFCs, SF_6, NF_3, if available)
		GHG Emission Intensity (Scope 1+2) (per rupee of turnover, per rupee of turnover adjusted for PPP, per physical output)
Principle 6 - E9	Embracing circularity - waste details	Provide details related to waste generated by category of waste
		Waste intensity (per rupee of turnover, per rupee of turnover adjusted for PPP, per physical output)
		Each category of waste generated, total waste recovered through recycling, re-using or other recovery operations

Page **6** of **7**

KPMG Assurance and Consulting Services LLP Gurugram

KPMG

Principle	Attribute / Area	Parameter / Metric
Principle 8 - E4	Principle 8 - E4	Enabling Inclusive Development
Principle 8 - E5		Wages paid to persons employed in smaller towns as % of total wage cost
Principle 9 - E7	Fairness in Engaging with Customers and Suppliers	Instances involving loss / breach of data of customers as a percentage of total data breaches or cyber security events

KPMG Assurance and Consulting Services LLP
Gurugram

Page 7 of 7